AAAAAA

   
Results: 1-8 |
Results: 8
PHASE-II STUDY OF RECEPTOR-ENHANCED CHEMOSENSITIVITY USING RECOMBINANT HUMANIZED ANTI-P185(HER2 NEU) MONOCLONAL-ANTIBODY PLUS CISPLATIN IN PATIENTS WITH HER2/NEU-OVEREXPRESSING METASTATIC BREAST-CANCER REFRACTORY TO CHEMOTHERAPY TREATMENT/
Authors: PEGRAM MD LIPTON A HAYES DF WEBER BL BASELGA JM TRIPATHY D BALY D BAUGHMAN SA TWADDELL T GLASPY JA SLAMON DJ
Citation: Md. Pegram et al., PHASE-II STUDY OF RECEPTOR-ENHANCED CHEMOSENSITIVITY USING RECOMBINANT HUMANIZED ANTI-P185(HER2 NEU) MONOCLONAL-ANTIBODY PLUS CISPLATIN IN PATIENTS WITH HER2/NEU-OVEREXPRESSING METASTATIC BREAST-CANCER REFRACTORY TO CHEMOTHERAPY TREATMENT/, Journal of clinical oncology, 16(8), 1998, pp. 2659-2671
PHASE-II STUDY OF WEEKLY INTRAVENOUS RECOMBINANT HUMANIZED ANTI-P185(HER2) MONOCLONAL-ANTIBODY IN PATIENTS WITH HER2 NEU-OVEREXPRESSING METASTATIC BREAST/
Authors: BASELGA J TRIPATHY D MENDELSOHN J BAUGHMAN S BENZ CC DANTIS L SKLARIN NT SEIDMAN AD HUDIS CA MOORE J ROSEN PP TWADDELL T HENDERSON IC NORTON L
Citation: J. Baselga et al., PHASE-II STUDY OF WEEKLY INTRAVENOUS RECOMBINANT HUMANIZED ANTI-P185(HER2) MONOCLONAL-ANTIBODY IN PATIENTS WITH HER2 NEU-OVEREXPRESSING METASTATIC BREAST/, Journal of clinical oncology, 14(3), 1996, pp. 737-744
RANDOMIZED TRIAL OF MNRGP120 HIV-1 VACCINE IN SYMPTOMLESS HIV-1 INFECTION
Authors: ERON JJ ASHBY MA GIORDANO MF CHERNOW M REITER WM DEEKS SG LAVELLE JP CONANT MA YANGCO BG PATE PG TORRES RA MITSUYASU RT TWADDELL T
Citation: Jj. Eron et al., RANDOMIZED TRIAL OF MNRGP120 HIV-1 VACCINE IN SYMPTOMLESS HIV-1 INFECTION, Lancet, 348(9041), 1996, pp. 1547-1551
NEUTRALIZING ANTIBODY-INDUCED BY (MN OR COMBINATION MN IIIB) RGP120/HIV-1 VACCINES IN LOW-RISK VOLUNTEERS/
Authors: BELSHE RB KEEFER M GRAHAM B MATTHEWS T TWADDELL T BERMAN P FAST P
Citation: Rb. Belshe et al., NEUTRALIZING ANTIBODY-INDUCED BY (MN OR COMBINATION MN IIIB) RGP120/HIV-1 VACCINES IN LOW-RISK VOLUNTEERS/, AIDS research and human retroviruses, 10, 1994, pp. 190000156-190000156
SAFETY AND IMMUNOGENICITY OF MN AND IIIB RGP120 HIV-1 VACCINES IN HIV-1-INFECTED SUBJECTS WITH CD4 COUNTS GREATER-THAN-500 CELLS/MM(3)/
Authors: ALLAN JD MITSUYASU R LAVELLE JP CONANT MA TWADDELL T KAHN JO
Citation: Jd. Allan et al., SAFETY AND IMMUNOGENICITY OF MN AND IIIB RGP120 HIV-1 VACCINES IN HIV-1-INFECTED SUBJECTS WITH CD4 COUNTS GREATER-THAN-500 CELLS/MM(3)/, AIDS research and human retroviruses, 10, 1994, pp. 190000157-190000157
THE SAFETY AND IMMUNOGENICITY OF RECOMBINANT ENVELOPE HIV VACCINES INASYMPTOMATIC HIV-INFECTED CHILDREN
Authors: LAMBERT JS MCNAMARA J KATZ S FENTON T DULIEGE AM VOLVOWITZ F TWADDELL T NICHOLS J ROBERTS NJ
Citation: Js. Lambert et al., THE SAFETY AND IMMUNOGENICITY OF RECOMBINANT ENVELOPE HIV VACCINES INASYMPTOMATIC HIV-INFECTED CHILDREN, AIDS research and human retroviruses, 10, 1994, pp. 190000159-190000159
NEUTRALIZING ANTIBODIES TO HIV-1 IN SERONEGATIVE VOLUNTEERS IMMUNIZEDWITH RECOMBINANT GP120 FROM THE MN STRAIN OF HIV-1
Authors: BELSHE RB GRAHAM BS KEEFER MC GORSE GJ WRIGHT P DOLIN R MATTHEWS T WEINHOLD K BOLOGNESI DP SPOSTO R STABLEIN DM TWADDELL T BERMAN PW GREGORY T IZU AE WALKER MC FAST P
Citation: Rb. Belshe et al., NEUTRALIZING ANTIBODIES TO HIV-1 IN SERONEGATIVE VOLUNTEERS IMMUNIZEDWITH RECOMBINANT GP120 FROM THE MN STRAIN OF HIV-1, JAMA, the journal of the American Medical Association, 272(6), 1994, pp. 475-480
INDUCTION OF HIV-1-NEUTRALIZING AND SYNCYTIUM-INHIBITING ANTIBODIES IN UNINFECTED RECIPIENTS OF HIV-1(IIIB) RGP120-SUBUNIT VACCINE
Authors: SCHWARTZ DH GORSE G CLEMENTS ML BELSHE R IZU A DULIEGE AM BERMAN P TWADDELL T STABLEIN D SPOSTO R SILICIANO R MATTHEWS T
Citation: Dh. Schwartz et al., INDUCTION OF HIV-1-NEUTRALIZING AND SYNCYTIUM-INHIBITING ANTIBODIES IN UNINFECTED RECIPIENTS OF HIV-1(IIIB) RGP120-SUBUNIT VACCINE, Lancet, 342(8863), 1993, pp. 69-73
Risultati: 1-8 |